Publications:  Prof Kanwal Pasi

Bowles L, Platton S, Yartey N, Dave M, Lee K, Hart DP, MacDonald V, Green L et al.(2020). Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19. N Engl J Med

Nolan B, Mahlangu J, Pabinger I, Young G, Konkle BA, Barnes C, Nogami K, Santagostino E et al.(2020). Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study. Haemophilia vol. 26, (3) 494-502.

Pierce GF, Pasi KJ, Coffin D, Kaczmarek R, Lillicrap D, Mahlangu J, Rottellini D, Sannié T et al.(2020). Towards a global multidisciplinary consensus framework on haemophilia gene therapy: Report of the 2nd World Federation of Haemophilia Gene Therapy Round Table. Haemophilia vol. 26, (3) 443-449.

Blacker E, MacDonald V, Hart DP, Bowles L, Cavenagh JD, Forsyth K, Morris A, Foley C et al. (2020). A case of acquired von Willebrand syndrome becoming IVIg responsive following bortezomib treatment despite minimal paraprotein response. BRITISH JOURNAL OF HAEMATOLOGY. vol. 189, 272-272.

Sivapalaratnam S, Muczynski V, Collins J, Pasi J, Downes K, Nathwani A, Gomez K (2020). Gain of function variant of prothrombin (p.R541W) causes dominant heritable thrombosis and is associated with antithrombin resistance. BRITISH JOURNAL OF HAEMATOLOGY. vol. 189, 42-43.

Pasi KJ, Rangarajan S, Mitchell N, Lester W, Symington E, Madan B, Laffan M, Russell CB et al.(2020). Multiyear follow-up of aav5-hfviii-sq gene therapy for hemophilia a. New England Journal of Medicine vol. 382, (1) 29-40.

Pasi KJ, Fischer K, Ragni M, Kulkarni R, Ozelo MC, Mahlangu J, Shapiro A, P¿Ng S et al.(2020). Long-term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B-YOND extension study. Haemophilia

Akay M, Zaidi A, Vaidya S, Sivapalaratnam S, Theodoulou A, Platton S, Hart D, Pasi J et al.(2019). A novel variant causing α2 antiplasmin deficiency: case report and experience in a UK centre. Br J Haematol vol. 187, (2) e42-e44.

Pipe S, Leebeek FWG, Ferreira V, Sawyer EK, Pasi J(2019). Clinical Considerations for Capsid Choice in the Development of Liver-Targeted AAV-Based Gene Transfer. Molecular Therapy - Methods and Clinical Development vol. 15, 170-178.

Stanford S, Pink R, Creagh D, Clark A, Lowe G, Curry N, Pasi J, Perry D et al.(2019). Adenovirus-associated antibodies in UK cohort of hemophilia patients: A seroprevalence study of the presence of adenovirus-associated virus vector-serotypes AAV5 and AAV8 neutralizing activity and antibodies in patients with hemophilia A. Res Pract Thromb Haemost vol. 3, (2) 261-267.

Prasannan N, Chatterjee B, Pasi J, McDonald V, Maposa W, Ricketts W, Lau K, Giaslakiotis K et al. (2019). A Case of Acquired Haemophilia secondary to Atypical Carcinoid Tumour. BRITISH JOURNAL OF HAEMATOLOGY. vol. 185, 196-196.

Booth CS, Bowles L, Hart D, Pasi J, Forsyth K, Morris A, Kaya B, McDonald V (2019). Double Double Trouble - Two Cases of Acquired Immune Thrombocytopenia Complicating Congenital Haemophilia. BRITISH JOURNAL OF HAEMATOLOGY. vol. 185, 137-137.

Pasi J, Georgiev P, Creagh MD, Lissitchkov T, Bevan D, Austin S, Hay CR, Hegemann I et al. (2019). The role of antithrombin lowering in patients with hemophilia: Hemostatic control pre- and post-fitusiran dosing interruption. HAEMOPHILIA. vol. 25, 33-34.

Lissitchkov T, Klukowska A, Pasi J, Kessler CM, Klamroth R, Liesner RJ, Belyanskaya L, Walter O et al.(2019). Efficacy and safety of simoctocog alfa (Nuwiq®) in patients with severe hemophilia A: a review of clinical trial data from the GENA program. Ther Adv Hematol vol. 10,

Shapiro AD, Pasi KJ, Ozelo MC, Kulkarni R, Barnowski C, Winding B, Szamosi J, Lethagen S(2019). Extending recombinant factor IX Fc fusion protein dosing interval to 14 or more days in patients with hemophilia B. Res Pract Thromb Haemost vol. 3, (1) 109-113.

Ito Y, Carss KJ, Duarte ST, Hartley T, Keren B, Kurian MA, Marey I, Charles P et al.(2018). De Novo Truncating Mutations in WASF1 Cause Intellectual Disability with Seizures. American Journal of Human Genetics vol. 103, (1) 144-153.

Rangarajan S, Walsh L, Lester W, Perry D, Madan B, Laffan M, Yu H, Vettermann C et al.(2017). AAV5-factor VIII gene transfer in severe hemophilia a. New England Journal of Medicine vol. 377, (26) 2519-2530.

Lissitchkov T, Rusen L, Georgiev P, Windyga J, Klamroth R, Gercheva L, Nemes L, Tiede A et al.(2017). PK-guided personalized prophylaxis with Nuwiq® (human-cl rhFVIII) in adults with severe haemophilia A. Haemophilia vol. 23, (5) 697-704.

Pasi KJ, Rangarajan S, Georgiev P, Mant T, Creagh MD, Lissitchkov T, Bevan D, Austin S et al.(2017). Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy. N Engl J Med

Shapiro AD, Mahlangu JN, Perry D, Pasi J, Quon DV, Chowdary P, Tsao E, Li S et al.(2017). Treatment of bleeding episodes with recombinant factor VIII Fc fusion protein in A-LONG study subjects with severe haemophilia A. Haemophilia vol. 23, (3) 392-399.

Konkle B, Pasi K, Young G, Recht M, Quon D, Tsao E, Winding B, Lethagen S et al. (2017). Long-term Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) Prophylaxis in Adults, Adolescents, and Children with Severe Hemophilia A: Longitudinal Analysis of A-LONG and ASPIRE Studies. HAEMOPHILIA. vol. 23, 21-22.

Iorio A, Barbara AM, Makris M, Fischer K, Castaman G, Catarino C, Gilman E, Kavakli K et al.(2017). Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: a case series. Haemophilia vol. 23, (2) 255-263.

Pasi KJ, Perry D, Mahlangu JN, Konkle B, Rangarajan S, Hanabusa H, Pabinger I, Brown SA et al. (2017). Dosing Regimens Before and During Long-Term Treatment With Recombinant Factor VIII Fc Fusion Protein (rFVIIIFC) in Adults And Adolescents With Severe Haemophilia A: an Updated Analysis Of The Aspire Study. HAEMOPHILIA. vol. 23, 89-90.

Nolan B, Young G, Mahlangu JN, Liesner R, Pasi KJ, Yuan H, Winding B, Ramirez-Santiago A et al. (2017). Dosing Regimens Before and During Long-Term Treatment with Recombinant Factor VIII FC Fusion Protein (rFVIIIFc) in Children with Severe Haemophilia A: An Updated Analysis of the ASPIRE Study. HAEMOPHILIA. vol. 23, 42-43.

Pasi J (2017). How to Make a Choice Among the Different Extended Half-life Products?. HAEMOPHILIA. vol. 23, 23-23.

Mahlangu JN, Shapiro AD, Pasi KJ, Ragni MV, Ozelo MC, Oldenburg J, Matsushita T, Baker RI et al. (2017). Individualised Prophylaxis with Recombinant Factor IX FC Fusion Protein (RFIXFC) in Adults/Adolescents With Haemophilia B: Updated Interim Results of the B-YOND Extension Study. HAEMOPHILIA. vol. 23, 85-86.

Rangarajan S, Georgiev P, Mant T, Creagh MD, Lissitchkov T, Bevan D, Austin S, Hay CR et al. (2017). Management of Bleed Events in the Phase 1 Study of Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia in Patients with and Without Inhibitors. HAEMOPHILIA. vol. 23, 20-21.

Pasi KJ, Georgiev P, Mant T, Creagh MD, Lissitchkov T, Bevan D, Austin S, Hay CR et al. (2017). Phase 1 and Phase 1/2 Extension Study of Fitusiran, an Investigational Rnai Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: Updated Results in Patients With Inhibitors. HAEMOPHILIA. vol. 23, 88-89.

Chowdary P, Georgiev P, Mant T, Creagh MD, Lissitchkov T, Bevan D, Austin S, Hay CR et al. (2017). Phase 1 and Phase 1/2 Extension Study of Fitusiran, an Investigational Rnai Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: Updated Results in Patients Without Inhibitors. HAEMOPHILIA. vol. 23, 118-119.

Pasi KJ, Fischer K, Ragni M, Nolan B, Perry DJ, Kulkarni R, Ozelo M, Mahlangu J et al.(2017). Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B. Thrombosis and Haemostasis vol. 117, (3) 508-518.

Miners AH, Krishnan S, Pasi KJ(2016). Predicting the outcomes of using longer-acting prophylactic factor VIII to treat people with severe hemophilia A: a hypothetical decision analysis. J Thromb Haemost vol. 14, (11) 2141-2147.

Shapiro AD, Kulkarni R, Ozelo M, Windyga J, Pasi KJ, Perry DJ, Desai C, Mei B (2016). ANALYSIS OF ANNUALIZED BLEEDING RATES AND BASELINE CHARACTERISTICS IN SUBJECTS WITH A 14-DAY OR LONGER DOSING INTERVAL IN THE PHASE 3 B-LONG STUDY OF RECOMBINANT FACTOR IX FC FUSION PROTEIN. AMERICAN JOURNAL OF HEMATOLOGY. vol. 91, E406-E406.

Pasi KJ, Georgiev P, Mant T, Creagh MD, Lissitchkov T, Bevan D, Austin S, Hay CR et al.(2016). A Subcutaneously Administered Investigational RNAi Therapeutic, Fitusiran (ALN-AT3), Targeting Antithrombin for Treatment of Hemophilia: Interim Results in Patients with Hemophilia A or B. HAEMOPHILIA vol. 22, 76-76.

Konkle BA, Pasi KJ, Perry DJ, Mahlangu J, Rangarajan S, Hanabusa H, Pabinger I, Lethagen S et al.(2016). Dosing regimens before and following long-term treatment with recombinant factor VIII Fc fusion protein (rFVIIIFc) in adults and adolescents with severe hemophilia A. HAEMOPHILIA vol. 22, 44-44.

Nolan B, Liesner R, Young G, Mahlangu J, Pasi KJ, Lethagen S, Cristiano LM, Yuan H et al.(2016). Dosing regimens before and following long-term treatment with recombinant factor VIII Fc fusion protein (rFVIIIFc) in children with severe hemophilia A. HAEMOPHILIA vol. 22, 48-49.

Klamroth R, Bichler J, Jansen M, Belyanskaya L, Knaub S, Kessler C, Pasi J(2016). Experience with Nuwiq (R) in clinical trials with previously treated paediatric and adult patients. HAEMOPHILIA vol. 22, 47-47.

Maposa W, Bowles L, Fenton R, Foley C, Hart DP, Morris A, Pasi J, Patel V et al.(2016). Link nurse teaching day to bring haemophilia to ward nurses. HAEMOPHILIA vol. 22, 29-29.

Mahlangu J, Ragni MV, Shapiro AD, Pasi KJ, Ozelo MC, Oldenburg J, Matsushita T, Baker RI et al.(2016). Long-term safety and efficacy of recombinant factor IX Fc fusion protein (rFIXFc) in adults/adolescents with hemophilia B: Longitudinal analysis of B-LONG and B-YOND. HAEMOPHILIA vol. 22, 47-47.

Kulkarni R, Pasi KJ, Liesner R, Hanabusa H, Feng J, Ferrante F, Mei B, Jain N(2016). Post hoc analysis to evaluate the effect of recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis in adults and adolescents with target joints and hemophilia B. HAEMOPHILIA vol. 22, 44-44.

Berntorp E, Hart D, Mancuso ME, d'Oiron R, Perry D, O'Mahony B, Kaczmarek R, Crato M et al.(2016). The first Team Haemophilia Education meeting, 2015, Amsterdam, The Netherlands. Eur J Haematol vol. 97 Suppl 83, 3-18.

Austin S, Chowdary P, Kadam A, Laffan M, Dolan G, Pasi J(2016). Use of long term prophylaxis in London haemophilia centres. HAEMOPHILIA vol. 22, 110-110.

Collins P, Chalmers E, Chowdary P, Keeling D, Mathias M, O'Donnell J, Pasi KJ, Rangarajan S et al.(2016). The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO. Haemophilia

Mahlangu J, Shapiro AD, Pasi KJ, Ragni MV, Ozelo MC, Oldenburg J, Matsushita T, Baker RI et al.(2016). Extended-Interval Prophylaxis with Recombinant Factor IX FC Fusion Protein (rFIXFc) in Adults/Adolescents with Haemophilia B: Interim Results of the B-YOND Extension Study. HAEMOPHILIA vol. 22, 46-47.

Pasi KJ, Pabinger I, Kerlin BA, Kulkarni R, Nolan B, Wang M, Liesner R, Brown SA et al.(2016). Long-Term Efficacy of Recombinant Factor VIII FC Fusion Protein (rFVIIIFC) Prophylaxis in Paediatric, Adolescent, and Adult Subjects with Target Joints and Severe Haemophilia A. HAEMOPHILIA vol. 22, 21-21.

Pasi KJ, Perry DJ, Mahlangu J, Konkle BA, Rangarajan S, Brown SA, Hanabusa H, Jackson S et al.(2016). Long-Term Safety and Efficacy of Recombinant Factor VIII FC Fusion Protein (rFVIIIFc) in Adults and Adolescents with Severe Haemophilia A: An Updated Interim Analysis of the Aspire Study. HAEMOPHILIA vol. 22, 64-65.

Windyga J, Kulkarni R, Shapiro AD, Ragni MV, Pasi KJ, Ozelo MC, Tsao E, Allen G et al.(2016). Low Bleeding Rates with Increase or Maintenance of Physical Activity in Patients Treated with Recombinant Factor IX FC Fusion Protein (rFIXFc) in the B-LONG and Kids B-LONG Studies. HAEMOPHILIA vol. 22, 19-20.

Nolan B, Young G, Mahlangu J, Liesner R, Pasi KJ, Lethagen S, Cristiano LM, Li X et al.(2016). Second Interim Analysis of the Aspire Study Evaluating Long-Term Safety and Efficacy of Recombinant Factor VIII FC Fusion Protein (rFVIIIFc) in Children with Severe Haemophilia A. HAEMOPHILIA vol. 22, 65-66.

Stephensen D, Patel V, Elliot K, Bowles L, Hart DP, Pasi J(2016). The Relationship Between Clinical Joint Health and Functional Ability in Adult Men with Haemophilia. HAEMOPHILIA vol. 22, 51-51.

Powell JS, Apte S, Chambost H, Hermans C, Jackson S, Josephson NC, Mahlangu JN, Ozelo MC et al.(2016). Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study. British Journal of Haematology vol. 168, (1) 124-134.

Nolan B, Mahlangu J, Perry D, Young G, Liesner R, Konkle B, Rangarajan S, Brown S et al.(2016). Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A. Haemophilia vol. 22, (1) 72-80.

Pasi KJ, Georgiev P, Mant T, Creagh MD, Lissitchkov T, Bevan D, Austin S, Hay CR et al. (2015). A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-AT3) Targeting Antithrombin for Treatment of Hemophilia: Interim Weekly and Monthly Dosing Results in Patients with Hemophilia A or B. BLOOD. vol. 126,

Mahlangu J, Shapiro AD, Pasi KJ, Ragni MV, Ozelo MC, Oldenburg J, Matsushita T, Baker RI et al. (2015). Extended-Interval Prophylaxis with rFIXFc in Adults and Adolescents with Hemophilia B: Interim Results of the B- YOND Extension Study. BLOOD. vol. 126,

Kerlin BA, Kulkarni R, Nolan B, Wang M, Pasi KJ, Liesner R, Brown S, Hanabusa H et al. (2015). Long-Term Efficacy of rFVIIIFc Prophylaxis in Pediatric, Adolescent, and Adult Subjects with Target Joints and Severe Hemophilia A. BLOOD. vol. 126,

Pasi KJ, Perry DJ, Mahlangu J, Konkle BA, Rangarajan S, Brown S, Hanabusa H, Jackson S et al. (2015). Long-Term Safety and Efficacy of rFVIIIFc in Adults and Adolescents with Severe Hemophilia A: A Longitudinal Analysis of A- LONG and ASPIRE. BLOOD. vol. 126,

Kulkarni R, Shapiro AD, Windyga J, Ragni MV, Pasi KJ, Ozelo MC, Tsao E, Mei B (2015). Low Bleeding Rates with Increase or Maintenance of Physical Activity in Patients Treated with Recombinant Factor IX Fc Fusion Protein ( rFIXFc) in the B-LONG and Kids B-LONG Studies. BLOOD. vol. 126,

Klamroth R, Lissitchkov T, Rusen L, Walter O, Bichler J, Pasi KJ, Tiede A, Knaub S (2015). Personalized Prophylaxis with Human-CI Recombinant FVIII in HA Patients. BLOOD. vol. 126,

Patel V, Hart D, Bowles L, Pasi J, Jawad A(2015). Intra-Articular Hyaluronate Injections in Severe Haemophilia Patients With Moderate to Severe Arthritis of the Ankle. HAEMOPHILIA vol. 21, (6) E549-E549.

Batty P, Moore GW, Platton S, Maloney JC, Palmer B, Bowles L, Pasi KJ, Rangarajan S et al.(2015). Diagnostic accuracy study of a factor VIII ELISA for detection of factor VIII antibodies in congenital and acquired haemophilia A. Thromb Haemost vol. 114, (4) 804-811.

Batty P, Honke A, Bowles L, Hart DP, Pasi KJ, Uprichard J, Austin SK(2015). Ongoing risk of thrombosis with factor XI concentrate: 5years experience in two centres. HAEMOPHILIA vol. 21, (4) 490-495.

Sorensen B, Mant T, Georgiev P, Rangarajan S, Pasi JK, Creagh D, Bevan DH, Austin S et al.(2015). A subcutaneously administered investigational RNAi therapeutic (ALN-AT3) targeting antithrombin for treatment of hemophilia: interim phase 1 study results in patients with hemophilia A or B. JOURNAL OF THROMBOSIS AND HAEMOSTASIS vol. 13, 176-177.

Gwynn S, Arya R, McPhelim J, Talbot T, Pasi J, Fortes-Mayer G, Kedia N, Kokiet S et al.(2015). Cancer associated thrombosis: developing consensus guidance to improve patient care and outcomes. JOURNAL OF THROMBOSIS AND HAEMOSTASIS vol. 13, 543-544.

Klamroth R, Lissitchkov T, Rusen L, Walter O, Knaub S, Bichler J, Pasi J, Tiede A(2015). Personalizedprophylaxis with Human-CL RHFVIII in hemophilia A patients. JOURNAL OF THROMBOSIS AND HAEMOSTASIS vol. 13, 850-851.

Young G, Mahlangu J, Kulkarni R, Nolan B, Liesner R, Pasi J, Barnes C, Neelakantan S et al.(2015). Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost vol. 13, (6) 967-977.

Nolan B, Young G, Mahlangu J, Liesner R, Pasi J, Cristiano LM, Li X, Pierce GF et al.(2015). Interim Analysis Of The ASPIRE Study Evaluating Long-term Safety And Efficacy Of Recombinant Factor VIII FC (RFVIIIFC) In Children With Severe Haemophilia A. HAEMOPHILIA vol. 21, 58-59.

Pasi J, Perry D, Mahlangu J, Konkle B, Rangarajan S, Brown SA, Hanabusa H, Jackson S et al.(2015). Long-Term Safety and Efficacy of Recombinant Factor VIII FC (RFVIIIFC) in Adults and Adolescents With Severe Haemophilia A: An Interim Analysis of The ASPIRE Study. HAEMOPHILIA vol. 21, 52-53.

Young G, Mahlangu J, Kulkarni R, Nolan B, Liesner R, Pasi J, Barnes C, Neelakantan S et al.(2015). Safety, Efficacy, and Pharmacokinetics of Recombinant Factor VIII FC Fusion Protein (RFVIIIFC) in Previously Treated Paediatric Subjects with Severe Haemophilia A (Kids A-LONG). HAEMOPHILIA vol. 21, 32-32.

Windyga J, Ragni M, Pasi J, Shapiro AD, Ozelo M, Innes A, Mei B(2015). Subject-Reported Changes in Physical Activity During The B-LONG Study of Recombinant Factor IX FC Fusion Protein (RFIXFC) For Severe Haemophilia B. HAEMOPHILIA vol. 21, 29-29.

Powell J, Shapiro A, Ragni M, Negrier C, Windyga J, Ozelo M, Pasi J, Baker R et al.(2015). Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates. British Journal of Haematology vol. 168, (1) 113-123.

Khair K, Batty P, Riat R, Bowles L, Burgess C, Chen YH, Hart D, Platton S et al.(2015). Wilate use in 47 children with von Willebrand disease: The North London paediatric haemophilia network experience. Haemophilia vol. 21, (1) e44-e50.

Powell JS, Ozelo M, Ragni MV, Pasi J, Perry DJ, Zhu Y, Mei B, Pierce GF et al.(2014). Predicting FIX Activity in Prophylaxis Patients Using Recombinant FIX Fc Fusion Protein for Treatment of Bleeding Episodes. BLOOD vol. 124, (21)

Quon DV, Mahlangu JN, Shapiro AD, Pasi J, Zhu Y, Pierce GF, Li L, Allen G (2014). Predicting FVIII Activity in Patients Who Use Recombinant FVIII Fc Fusion Protein for Prophylaxis and Treatment of Bleeding Episodes. BLOOD. vol. 124,

Young G, Mahlangu JN, Kulkarni R, Nolan B, Liesner R, Pasi J, Barnes C, Neelakantan S et al. (2014). Safety, Efficacy, and Pharmacokinetics of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously-Treated Children with Severe Hemophilia a (Kids-ALONG). BLOOD. vol. 124,

Shapiro AD, Ragni MV, Kulkarni R, Oldenberg J, Srivastava A, Quon DV, Pasi KJ, Hanabusa H et al.(2014). Recombinant factor VIII Fc fusion protein: Extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. Journal of Thrombosis and Haemostasis vol. 12, (11) 1788-1800.

Batty P, Platton S, Bowles L, Pasi KJ, Hart DP(2014). Pre-analytical heat treatment and a FVIII ELISA improve Factor VIII antibody detection in acquired haemophilia A. Br J Haematol vol. 166, (6) 953-956.

Batty P, Chen YH, Bowles L, Hart DP, Platton S, Pasi KJ(2014). Safety and efficacy of a von Willebrand factor/factor VIII concentrate (Wilate®): A single centre experience. Haemophilia

Young G, Mahlangu J, Kulkarni R, Nolan B, Liesner R, Pasi J, Barnes C, Neelakantan S et al. (2014). KIDS A-LONG: SAFETY, EFFICACY, AND PHARMACOKINETICS OF LONG-ACTING RECOMBINANT FACTOR VIII FC FUSION PROTEIN (RFVIIIFC) IN PREVIOUSLY-TREATED PAEDIATRIC SUBJECTS WITH HAEMOPHILIA A. HAEMATOLOGICA. vol. 99, 791-791.

Kulkarni R, Ragni MV, Baker RI, Pasi J, Manco-Johnson MJ, Potts J, Brennan A, Pierce GF(2014). Analysis of clinical target joint bleeding on prophylactic regimens with recombinant Factor VIII Fc fusion protein in patients with severe hemophilia A. HAEMOPHILIA vol. 20, 94-94.

Fong F, Davies J, Fearne J, Pasi J(2014). Dental care pathway for children with hematological disorders. HAEMOPHILIA vol. 20, 132-132.

Pasi J, Ragni M, Ozelo M, Valentino LA, Jiang H, Dodd N, Robinson B, Mei B et al.(2014). Recombinant factor IX Fc fusion protein as episodic treatment for bleeding: Analysis from the B-LONG Study. HAEMOPHILIA vol. 20, 15-16.

Negrier C, Powell J, Shapiro A, Ragni M, Windyga J, Ozelo M, Pasi J, Baker R et al.(2014). Recombinant factor IX Fc fusion protein dosing conversion: extended-interval dosing yields low bleeding rates and a reduction in factor consumption. HAEMOPHILIA vol. 20, 187-187.

Oldenberg J, Shapiro AD, Ragni MV, Kulkarni R, Srivastava A, Quon DV, Pasi KJ, Hanabusa H et al.(2014). Switching to treatment with recombinant factor VIII Fc fusion protein: extended dosing interval yields low bleeding rates with comparable factor consumption and is correlated with von Willebrand Factor levels. HAEMOPHILIA vol. 20, 187-187.

Pasi J, Potts J, Li S, Brennan A, Pierce GF, Jiang H(2014). Recombinant factor VIIIFc fusion protein in severe haemophilia A: association between bleeding and FVIII activity in A-LONG. HAEMOPHILIA vol. 20, 78-79.

Mahlangu J, Powell JS, Ragni MV, Chowdary P, Josephson NC, Pabinger I, Hanabusa H, Gupta N et al.(2014). Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. BLOOD vol. 123, (3) 317-325.

Powell JS, Pasi KJ, Ragni MV, Ozelo MC, Valentino LA, Mahlangu JN, Josephson NC, Perry D et al.(2013). Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B. NEW ENGLAND JOURNAL OF MEDICINE vol. 369, (24) 2313-2323.

Mahlangu J, Powell J, Ragni M, Chowdary P, Josephson N, Pabinger I, Hanabusa H, Gupta N et al.(2013). A-LONG: results from a Phase 3 study of safety, efficacy, and pharmacokinetics of long-lasting recombinant factor VIII Fc fusion protein (rFVIIIFc). JOURNAL OF THROMBOSIS AND HAEMOSTASIS vol. 11, 168-169.

Li S, Diao L, Powell J, Shapiro AD, Josephson N, Pasi J, Perry D, Ragni M et al.(2013). Clinical implications of population pharmacokinetics of rFIXFc in routine prophylaxis, control of bleeding and perioperative management for haemophilia B patients. JOURNAL OF THROMBOSIS AND HAEMOSTASIS vol. 11, 358-359.

Platton SJ, Batty P, Bowles L, Pasi J, Hart DP(2013). Heat treatment and immunological testing substantially improves the detection of factor VIII antibodies in acquired haemophilia A. JOURNAL OF THROMBOSIS AND HAEMOSTASIS vol. 11, 670-670.

Batty P, Moore GW, Platton SJ, Maloney JC, Bowles L, Pasi J, Rangarajan S, Hart DP(2013). Immunological detection of factor VIII antibodies in congenital and acquired haemophilia A. JOURNAL OF THROMBOSIS AND HAEMOSTASIS vol. 11, 930-930.

Mahlangu J, Powell J, Josephson N, Klamroth R, Parra Lopez R, Morfini M, Oldenburg J, Pasi J et al.(2013). Long-lasting recombinant factor VIII Fc fusion (rFVIIIFc) for perioperative management of subjects with haemophilia A in the phase 3 A-LONG study. JOURNAL OF THROMBOSIS AND HAEMOSTASIS vol. 11, 459-459.

Batty P, Honke A, Uprichard J, Bowles L, Hart DP, Pasi J, Austin S(2013). Ongoing risk of thrombosis with factor XI concentrate: 5 years experience in two centres. JOURNAL OF THROMBOSIS AND HAEMOSTASIS vol. 11, 708-708.

Neelakantan S, Li S, Powell J, Josephson N, Pasi J, Perry D, Shapiro AD, Ragni M et al.(2013). Population pharmacokinetic analysis of long-lasting recombinant factor VIII Fc fusion protein (rFVIIIFc) in patients with severe haemophilia A. JOURNAL OF THROMBOSIS AND HAEMOSTASIS vol. 11, 354-355.

Batty P, Chen YH, Platton SJ, Bowles L, Hart DP, Pasi J(2013). Safety and efficacy of a von Willebrand factor/factor VIII concentrate (Wilate (R)): a single centre experience. JOURNAL OF THROMBOSIS AND HAEMOSTASIS vol. 11, 548-548.

Ragni M, Josephson N, Mahlangu J, Pasi J, Perry D, Powell J, Shapiro AD, Krassova S et al.(2013). Treatment of bleeding episodes in subjects with haemophilia A with long-lasting recombinant Factor VIII Fc fusion protein (rFVIIIFc) in the Phase 3 A-LONG study. JOURNAL OF THROMBOSIS AND HAEMOSTASIS vol. 11, 928-929.

Pasi J, Josephson N, Mahlangu J, Perry D, Powell J, Ragni M, Valentino LA, Krassova S et al.(2013). Treatment of bleeding episodes in subjects with haemophilia B with the long-lasting recombinant factor IX Fc fusion protein (rFIXFc) in the phase 3 B-LONG study. JOURNAL OF THROMBOSIS AND HAEMOSTASIS vol. 11, 359-359.

Mahlangu J, Powell J, Ragni M, Chowdary P, Josephson N, Pabinger-Fasching I, Hanabusa H, Gupta N et al.(2013). Phase 3 clinical study of recombinant FC fusion factor FVIII (RFVIIIFC) demonstrated safety, efficacy, and improved pharmacokinetics (A-LONG). HAEMOPHILIA vol. 19, 70-71.

Powell J, Ozelo M, Pasi J, Ragni M, Valentino L, Mahlangu J, Josephson N, Perry D et al.(2013). Safety, efficacy, and improved pharmacokinetics (PK) demonstrated in a phase 3 clinical trial of extended half-life recombinant FC fusion factor IX (B-LONG). HAEMOPHILIA vol. 19, 76-77.

Raza I, Davenport R, Rourke C, Platton S, Manson J, Spoors C, Khan S, De'Ath HD et al.(2013). The incidence and magnitude of fibrinolytic activation in trauma patients. J Thromb Haemost vol. 11, (2) 307-314.

Davidson SL, Theodoulou A, Kempley ST, Pasi J(2013). A rare cause of neonatal hydrocephalus. Case Rep Perinat Med vol. 2, (1-2) 71-73.

Wong W-Y, Bevan D, Sorensen B, Pasi J, Benson G, Dockal M, Conlan M, Cecerle M et al.(2012). Treatment of hemophilia A and B with BAX 499, an aptamer based specific inhibitor of TFPI - Summary data of a clinical phase 1 trial. HAEMOPHILIA vol. 18, (5) 831-831.

Batty P, Platton S, Hart D, Pasi J(2012). An unusual cause of bleeding in an elderly patient. CLINICAL MEDICINE vol. 12, (4) 397-397.

Kalsi H, Nanayakkara L, Pasi KJ, Bowles L, Hart DP(2012). Access to primary dental care for patients with inherited bleeding disorders. Haemophilia vol. 18, (4) 510-515.

Islam A, Doly E, Yunnus A, Kabir A, Islam N, Mathias M, Mclaughlin P, Hubert N et al.(2012). Hemophilia 2012-London-Moscow-Dhaka: A Comparative, Observational Study of the Musculoskeletal Impact of Severe Hemophilia in Twenty Boys in Each City. HAEMOPHILIA vol. 18, 193-193.

Osias A, Sager R, Danga E, Morris A, Forsyth K, Adetona T, Williams H, Townsend P et al.(2012). Implementation of an online home treatment record-keeping system (Haemtrack) in a large London comprehensive care centre. HAEMOPHILIA vol. 18, 59-59.

Bowles L, Pasi J, Hart D, Morris A, Forsyth K, Sager R, Danga E, Osias A et al.(2012). Ovarian endometrioma in two women with Glanzmann's thrombasthenia. HAEMOPHILIA vol. 18, 203-204.

Kalsi H, Nanayakkara L, Danga E, Bowles L, Jones J, Pasi J, Hart D(2012). Regular primary dental care access for patients with inherited bleeding disorders: The barriers and solutions. HAEMOPHILIA vol. 18, 48-48.

Shapiro A, Pasi J, Gust S, DeFeo-Fraulini T, Thomas G, Li L, Dabora S, Krassova S et al.(2012). Clinical Evaluation of a Novel, Long-Lasting Recombinant Fc Fusion Replacement Factor (Rfixfc) in Patients with Severe Hemophilia B. AMERICAN JOURNAL OF HEMATOLOGY vol. 87, S174-S174.

Bowles L, Morris A, Forsyth K, Sager R, Osias A, Danga E, Townsend P, Murphy U et al. (2012). Computerised patient records enhance communication, audit potential and patient safety in a large haemophilia comprehensive care centre. BRITISH JOURNAL OF HAEMATOLOGY. vol. 157, 39-39.

Shapiro A, Pasi J, Gust S, Defeofraulini T, Thomas G, Li L, Dabora S, Krassova S et al.(2012). Clinical evaluation of a novel, long-lasting recombinant Fc fusion replacement factor (rFIXFc) in patients with severe haemophilia B. HAEMOPHILIA vol. 18, 40-40.

Auerswald G, Salek SZ, Benson G, Elezovic I, Lambert T, Morfini M, Pasi J, Remor E et al.(2012). Beyond patient benefit: clinical development in hemophilia. HEMATOLOGY vol. 17, (1) 1-8.

Nathwani AC, Tuddenham EGD, Rangarajan S, Rosales C, McIntosh J, Linch DC, Chowdary P, Riddell A et al.(2011). Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med vol. 365, (25) 2357-2365.

Davenport R, Manson J, De'Ath H, Platton S, Coates A, Allard S, Hart D, Pearse R et al.(2011). Functional definition and characterization of acute traumatic coagulopathy. Crit Care Med vol. 39, (12) 2652-2658.

Nathwani AC, Tuddenham EGD, Rangarajan S, Rosales C, McIntosh JH, Linch DC, Chowdary P, Griffioen A et al. (2011). Adeno-Associated Viral Vector Mediated Gene Transfer for Hemophilia B. BLOOD. vol. 118, 4-5.

Pasi KJ(2011). Haemophilia and adolescence. HAEMOPHILIA vol. 17, 16-20.

Agarwal N, Willmott FJ, Bowles L, Pasi KJ, Beski S(2011). Case report of Grey Platelet Syndrome in pregnancy. Haemophilia vol. 17, (5) 825-826.

Davenport R, Rourke C, Manson J, De'Ath H, Platton S, Coates A, Hart D, Pearse P et al.(2011). Activated protein C is a principle mediator of acute traumatic coagulopathy. J THROMB HAEMOST vol. 9, 51-52.

Keeney S, Collins P, Cumming A, Goodeve A, Pasi J(2011). Diagnosis and Management of von Willebrand Disease in the United Kingdom. SEMIN THROMB HEMOST vol. 37, (5) 488-494.

Raza I, Davenport R, Rourke C, Platton S, Manson J, Spoors C, De'Ath H, Khan S et al.(2011). Occult activation of fibrinolysis in trauma. JOURNAL OF THROMBOSIS AND HAEMOSTASIS vol. 9, 848-848.

Curry NS, Rourke C, Khan S, Kingsland SA, Allard S, Pasi J, Brohi K, Stanworth S (2011). Fibrinogen replacement for major haemorrhage in trauma - an in-vitro study. BRITISH JOURNAL OF HAEMATOLOGY. vol. 153, 2-2.

Davenport R, Manson J, De'Ath H, Platton S, Coates A, Allard S, Hart D, Pearse R et al. (2011). Point of care diagnostics for the rapid identification of acute traumatic coagulopathy and prediction of massive trauma haemorrhage. BRITISH JOURNAL OF SURGERY. vol. 98, 7-7.

Noble S, Pasi J(2010). Epidemiology and pathophysiology of cancer-associated thrombosis. BRIT J CANCER vol. 102, S2-S9.

Bayele HK, Murdock PJ, Pasi KJ(2010). Residual Factor VIII-like cofactor activity of thioredoxin and related oxidoreductases. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS vol. 1800, (3) 398-404.

Perry D, Berntorp E, Tait C, Dolan G, Holme PA, Laffan M, Lassila R, Mumford A et al.(2010). FEIBA prophylaxis in haemophilia patients: a clinical update and treatment recommendations. HAEMOPHILIA vol. 16, (1) 80-89.

Astermark J, Negrier C, Hermans C, Holme PA, Klamroth R, Kotsi P, De Moerloose P, Pasi J et al.(2009). European curriculum for thrombosis and haemostasis. HAEMOPHILIA vol. 15, (1) 337-344.

Davenport R, Coates A, Allard S, Pasi J, MacCallum P, Stanworth S, Thiemermann C, Pearse R et al. (2009). TRAUMA HAEMORRHAGE: EVOLVING ROLE OF ROTEM FOR PREDICTING TRANSFUSION REQUIREMENTS. SHOCK. vol. 32, 15-15.

Pasi J, Langley K, Booth J, Djakov V, Dunn R, Jones G(2008). Evaluation of novel micro-electro-mechanical sensors (MEMS) for measuring real-time blood coagulation. HAEMOPHILIA vol. 14, 26-26.

Moore G, Collins P, Cumming T, Laffan M, Pasi K, Lester W(2008). Management of von Willebrand disease in the peripartum period - a UK based survey. HAEMOPHILIA vol. 14, 155-155.

Young G, Ebbesen LS, Viuff D, Di Paola J, Konkle BA, Negrier C, Pasi J, Ingerslev J(2008). Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in haemophofoa A and B patients with inhibitors: a multicentre trial. BLOOD COAGUL FIBRIN vol. 19, (4) 276-282.

Haberichter SL, Castarnan G, Budde U, Peake I, Goodeve A, Rodeghiero F, Federici AB, Batlle J et al.(2008). Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: Molecular and Clinical Markers for the Diagnosis and Management of Type 1 VWD (MCMDM-1VWD). BLOOD vol. 111, (10) 4979-4985.

Budde U, Schneppenheim R, Eikenboom J, Goodeve A, Will K, Drewke E, Castaman G, Rodeghiero F et al.(2008). Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). J THROMB HAEMOST vol. 6, (5) 762-771.

Madhani M, Pasi KJ, Gutteridge CN, Ratnasabapathy S, Kakkar AK, MacCallum PK (2008). Preventing venous thromboembolism (VTE) in hospitalised patients: putting guidance into practice. BRITISH JOURNAL OF HAEMATOLOGY. vol. 141, 83-83.

Castaman G, Lethagen S, Federici AB, Tosetto A, Goodeve A, Budde U, Batlle J, Meyer D et al.(2008). Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. BLOOD vol. 111, (7) 3531-3539.

PASI KJ, Mazurier C, Schneppenheim R, Budde U, Ingerslev J, Vorlova Z, Habart D, Holmberg L et al.(2007). Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1VWD). Journal of Thrombosis & Haemostasis vol. 5, (4) 715-721.

PASI KJ, EIKENBOOM J, LAMBERT F, BARONCIANI L, FEDERICI AB, RODEGHIERO F, MEYER D, BATLLE J et al.(2007). Phenotype and Genotype of a Cohort of Families Diagnosed with Type 1 von Willebrand Disease in the European Study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). BLOOD vol. 109, 112-121.

Cumming A, Grundy P, Keeney S, Lester W, Enayat S, Guilliatt A, Bowen D, Pasi J et al.(2006). An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type I von Willebrand disease. THROMB HAEMOSTASIS vol. 96, (5) 630-641.

Tosetto A, Rodeghiero F, Castaman G, Goodeve A, Federici AB, Batlle J, Meyer D, Fressinaud E et al.(2006). A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J THROMB HAEMOST vol. 4, (4) 766-773.

Eikenboom J, Van Marion V, Putter H, Goodeve A, Rodeghiero F, Castaman G, Federici AB, Batlle J et al.(2006). Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD. J THROMB HAEMOST vol. 4, (4) 774-782.

Butcher JH, Pasi KJ(2006). Fatal postoperative pulmonary embolism in mild haemophilia. HAEMOPHILIA vol. 12, (2) 179-182.

Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD et al.(2005). Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. NEW ENGL J MED vol. 353, (1) 33-45.

Wright JR, Thompson J, Singh RK, Brouilette S, Pasi J, Samani NJ, Goodall AH (2005). Increased levels of procoagulant factors associated with increased potential for thrombin generation in patients with premature myocardial infarction. HEART. vol. 91,

Irving PM, Pasi KJ, Rampton DS(2005). Thrombosis and inflammatory bowel disease. Clin Gastroenterol Hepatol vol. 3, (7) 617-628.

Pasi KJ(2005). Von Willebrand's disease -- awareness influences diagnosis. Indian J Med Res vol. 121, (5) 628-630.

Cumming- A, Grundy P, Keeney S, Collins P, Bowen D, Lester W, Enayat S, Guilliatt A et al. (2005). A UKHCDO national study of the molecular pathogenesis of type 1 von Willebrand disease (VWD). BRITISH JOURNAL OF HAEMATOLOGY. vol. 129, 4-4.

Ludlam CA, Pasi KJ, Bolton-Maggs P, Collins PW, Cumming AM, Dolan G, Fryer A, Harrington C et al.(2005). A framework for genetic service provision for haemophilia and other inherited bleeding disorders. HAEMOPHILIA vol. 11, (2) 145-163.

Bowen DJ, Collins PW, Lester W, Cumming AM, Keeney S, Grundy P, Enayat SM, Bolton-Maggs PHB et al.(2005). The prevalence of the cysteine1584 variant of von Willebrand factor is increased in type 1 von Willebrand disease: co-segregation with increased susceptibility to ADAMTS13 proteolysis but not clinical phenotype. BRIT J HAEMATOL vol. 128, (6) 830-836.

PASI KJ, FLORENCE AT, TOTH I, LEE CA, BAYELE HK, WILDERSPIN AF, O'DONELL M, SAKTHIVEL T(2005). Versatile peptide dendrimers for nucleic acid delivery. J Pharm Sci vol. 94, (2) 446-457.

Miall FM, Deol PS, Barnes TA, Dampier K, Watson CC, Oppenheimer CA, Pasi KJ, Pavord SR(2005). Coagulation status and complications of pregnancy. Thromb Res vol. 115, (6) 461-467.

PASI KJ, VIDLER V, WILLIAMS MD, CHAMERS EA, RICHARDS M, THOMAS A, BROWN SA, LIESNER R et al.(2005). Management of neonates with inherited bleeding disorders - a survey of current UK practice. Haemophilia, vol. 11, 186-187.

PASI KJ, ROTH DA, ROTHSCHILD C, NEGRIER C, LUSHER JD, HOOTS WK, ABSHIRE TC, BLANCHETTE VS et al.(2005). The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. Blood vol. 105, 518-525.

Walewska RJ, Dunnion DJ, Pasi KJ, Browning MJ (2004). Development of cell based therapeutic vaccines for the treatment of multiple myeloma. BLOOD. vol. 104, 417A-418A.

Gomez K, Laffan MA, Kemball-Cook G, Pasi J, Layton M, Singer JD, Tuddenham EGD, McVey JH(2004). Two novel mutations in severe factor VII deficiency. BRIT J HAEMATOL vol. 126, (1) 105-110.

Pasi KJ, Collins PW, Keeling DM, Brown SA, Cumming AM, Dolan GC, Hay CRM, Hill FGH et al.(2004). Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia vol. 10, (3) 218-231.

Laffan M, Brown SA, Collins PW, Cumming AM, Hill FGH, Keeling D, Peake IR, Pasi KJ(2004). The diagnosis of von Willebrand disease: A guideline from the UK Haemophilia Centre Doctors' Organization. HAEMOPHILIA vol. 10, (3) 199-217.

O'Donnell J, Riddell A, Owens D, Handa A, Pasi J, Hamilton G, Perry DJ(2004). Role of the thrombelastograph as an adjunctive test in thrombophilia screening. BLOOD COAGUL FIBRIN vol. 15, (3) 207-211.

Galiñanes M, Loubani M, Davies J, Chin D, Pasi J, Bell PR(2004). Autotransplantation of unmanipulated bone marrow into scarred myocardium is safe and enhances cardiac function in humans. Cell Transplant vol. 13, (1) 7-13.

RAHMAN MA, PASI KJ, MACLEAN N, GOLDSPINK G, FARAHMAND H, WILLIAMS DW, HWANG GL, MURDOCK PJ et al.(2004). Fish as bioreactors: Transgene expression of human coagulation factor VII in fish embryos. Marine Biotechnology, vol. 6, 485-492.

Ludlam CA, Pasi KJ, Collins PW, Maggs PHBB, Cumming AM, Dolan G, Fryer A, Hill FGH et al.(2004). Gene therapy trials in the UK: is haemophilia a suitable 'model'?. CLIN MED vol. 4, (1) 54-56.

PASI KJ, PAVORD SR, BARNES TA, DEOL PS, DAMPIER K, OPPENHEIMER C(2004). The effects of folic acid supplements on coagulation status in pregnancy. British Journal of Haematology, vol. 127, 204-208.

Eikenboom JCJ, van Marion V, Putter H, Garcia EBG, Peake I, Goodeve A, Rodeghiero F, Castaman G et al. (2003). Analysis of cosegregation of type 1 Von Willebrands disease phenotype and von Willebrand factor gene haplotypes in the European Multicenter MCMDM-1VWD study. BLOOD. vol. 102, 90A-90A.

Goodeve A, Walker M, Peake I, Rodeghiero F, Castaman G, Federici A, Batlle J, Meyer D et al. (2003). Contribution of ABO blood group to type 1 von Willebrand disease in patients entered in the multicentre MCMDM-1VWD study. BLOOD. vol. 102, 91A-91A.

Lester WA, Bowen DJ, Cumming A, Collins PW, Watson P, Keeney S, Enayat MS, Keeling D et al. (2003). Variable phenotypic penetrance of von Willebrand factor gene Y1584C heterozygosity in type 1 von Willebrand disease families and its association with enhanced in vitro susceptibility to ADAMTS 13 mediated proteolysis. BLOOD. vol. 102, 311A-311A.

Wright JR, Singh RK, Qamar N, Pasi J, Samani NJ, Goodall AH (2003). Premature myocardial infarction is associated with increased thrombin generation. ATHEROSCLEROSIS. vol. 170, S5-S5.

Bolton-Maggs PHB, Pasi KJ(2003). Haemophilias A and B. LANCET vol. 361, (9371) 1801-1809.

PASI KJ, YOONG WC, PERRY DJ, OWENS D, TUCK SM(2003). Markers of platelet activation, thrombin generation and fibrinolysis in women with sickle cell disease: effects of differing forms of hormonal contraception. European Journal of Haematology vol. 70, 310-314.

PASI KJ, BOLTON-MAGGS PH(2003). The Haemophilias. Lancet vol. 361, 1801-1809.

Galinanes M, Loubani M, Davies J, Chin D, Pasi J, Bell P (2002). Safety and efficacy of transplantation of autologous bone marrow into scarred myocardium for the enhancement of cardiac function in man. CIRCULATION. vol. 106, 463-463.

Behrmann M, Pasi J, Saint-Remy JMR, Kotitschke R, Kloff M(2002). Von Willebrand factor modulates factor VIII immunogenicity: Comparative study of different factor VIII concentrates in a haemophilia A mouse model. THROMB HAEMOSTASIS vol. 88, (2) 221-229.

PASI KJ, PERRY DJ, LEE CA, GOLDSPINK G, MILLER R, FIELDS PA(2002). Somatic gene therapy for haemophilia: some counselling issues for today and tomorrow. Psychology, Health and Medicine vol. 6, (2) 163-173.

Bayele HK, Murdock PJ, Perry DJ, Pasi KJ(2002). Simple shifts in redox/thiol balance that perturb blood coagulation. FEBS LETT vol. 510, (1-2) 67-70.

PASI KJ, GIANGRANDE PLF, WHITE GC, RAGNI MV, TUBRIDY K, COURTER SG(2002). Use of recombinant factor IX in subjects with haemophilia B undergoing surgery. Haemophilia vol. 8, 91-97.

Pasi KJ(2001). Gene therapy for haemophilia. Br J Haematol vol. 115, (4) 744-757.

PASI KJ, TUBRIDY K, ROTH DA, COURTER SG, KESSLER CM, RUP B(2001). Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood vol. 98, (13) 3600-3606.

Woolston CM, Pringle HJ, Pasi J(2001). HL60 are protected from drug induced apoptosis when cocultured with CD34-ve primary bone marrow stromal cells. BLOOD vol. 98, (11) 183B-183B.

Rye AD, Tucker VC, Patel R, Pasi KJ, Browning MJ(2001). Telomere maintenance in the monoclonal gammopathies and multiple myeloma. BLOOD vol. 98, (11) 303B-303B.

Enayat MS, Guilliatt AM, Surdhar GK, Jenkins PV, Pasi KJ, Toh CH, Williams MD, Hill FGH(2001). Aberrant dimerization of von Willebrand factor as the result of mutations in the carboxy-terminal region: identification of 3 mutations in members of 3 different families with type 2A (phenotype IID) von Willebrand disease. BLOOD vol. 98, (3) 674-680.

Nitu-Whalley IC, Riddell A, Lee CA, Pasi KJ, Owens D, Enayat MS, Perkins SJ, Jenkins PV(2000). Identification of type 2 von Willebrand disease in previously diagnosed type 1 patients. a reappraisal using phenotypes, genotypes and molecular modelling. THROMB HAEMOSTASIS vol. 84, (6) 998-1004.

Shapiro A, Abshire T, Kisker T, Lee C, Pasi J, Pollmann H, Nguyen K, Nissen S et al.(2000). Recombinant factor IX (rFIX) treatment of previously untreated patients (PUPs) with severe or moderately severe hemophilia B. BLOOD vol. 96, (11) 264A-265A.

Yee TT, Taher A, Pasi KJ, Lee CA(2000). A survey of patients with acquired haemophilia in a haemophilia centre over a 28-year period. Clin Lab Haematol vol. 22, (5) 275-278.

Pasi KJ, Sabin CA, Jenkins PV, Devereux HL, Ononye C, Lee CA(2000). The effects of the 32-bp CCR-5 deletion on HIV transmission and HIV disease progression in individuals with haemophilia. Br J Haematol vol. 111, (1) 136-142.

Hilbert L, Jenkins PV, Gaucher C, Meriane E, Collins PW, Pasi KJ, Mazurier C(2000). Type 2M vWD resulting from a lysine deletion within a four lysine residue repeat in the A1 loop of von Willebrand factor. Thromb Haemost vol. 84, (2) 188-194.

Millar DS, Elliston L, Deex P, Krawczak M, Wacey AI, Reynaud J, Nieuwenhuis HK, Bolton-Maggs P et al.(2000). Molecular analysis of the genotype-phenotype relationship in factor X deficiency. Hum Genet vol. 106, (2) 249-257.

Nitu-Whalley IC, Lee CA, Griffioen A, Jenkins PV, Pasi KJ(2000). Type 1 von Willebrand disease - a clinical retrospective study of the diagnosis, the influence of the ABO blood group and the role of the bleeding history. Br J Haematol vol. 108, (2) 259-264.

Murphy KM, Pasi J, Reid W, Perry DJ(1999). Audit of low molecular weight heparin usage in prophylaxis of venous thromboembolism (VTE) in pregnancy. BRITISH JOURNAL OF HAEMATOLOGY vol. 105, 43-43.

Yee TT, Pasi KJ, Lilley PA, Lee CA(1999). Factor VIII inhibitors in haemophiliacs: a single-centre experience over 34 years, 1964-97. Br J Haematol vol. 104, (4) 909-914.

Harrison P, Robinson MS, Mackie IJ, Joseph J, McDonald SJ, Liesner R, Savidge GF, Pasi J et al.(1999). Performance of the platelet function analyser PFA-100 in testing abnormalities of primary haemostasis. Blood Coagul Fibrinolysis vol. 10, (1) 25-31.

Fields PA, Pasi KJ(1998). Gene therapy for haemophilia: how far have we come?. Haemophilia vol. 4, (5) 699-703.

Jenkins PV, Ononye C, Pasi KJ(1998). Identification of a novel candidate mutation causing 2A (IID) von Willebrand's disease. THROMBOSIS RESEARCH vol. 91, (3) S16-S16.

Jenkins PV, Pasi KJ, Perkins SJ(1998). Molecular modelling of ligand and mutation sites of the A1 and A2 domains of human von Willebrand factor and their relevance to von Willebrand's disease. BRITISH JOURNAL OF HAEMATOLOGY vol. 101, 85-85.

Jenkins PV, Pasi KJ, Perkins SJ(1998). Molecular modeling of ligand and mutation sites of the type A domains of human von Willebrand factor and their relevance to von Willebrand's disease. Blood vol. 91, (6) 2032-2044.

Schulman S, d'Oiron R, Martinowitz U, Pasi J, Briquel ME, Mauser-Bunschoten E, Morfini M, Ritchie B et al. (1998). Experiences with continuous infusion of recombinant activated factor VII. Blood Coagul Fibrinolysis. vol. 9 Suppl 1, S97-101.

Evans G, Pasi KJ, Mehta A, Lee CA, Perry DJ(1997). Recurrent venous thromboembolic disease and factor XI concentrate in a patient with severe factor XI deficiency, chronic myelomonocytic leukaemia, factor V Leiden and heterozygous plasminogen deficiency. Blood Coagul Fibrinolysis vol. 8, (7) 437-440.

Murdock PJ, Woodhams BJ, Matthews KB, Pasi KJ, Goodall AH(1997). von Willebrand factor activity detected in a monoclonal antibody-based ELISA: an alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use. Thromb Haemost vol. 78, (4) 1272-1277.

Yee TT, Williams MD, Hill FG, Lee CA, Pasi KJ(1997). Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a single intermediate purity factor VIII product. Thromb Haemost vol. 78, (3) 1027-1029.

Pasi KJ (1997). Previously untreated patients and recombinant factor VIII concentrate studies. Blood Coagul Fibrinolysis. vol. 8 Suppl 1, S29-S32.

Jenkins PV, Pasi KJ, Ononye C, Perkins SJ(1997). A molecular graphics model of the A1 and A2 domains of von Willebrand factor. THROMBOSIS AND HAEMOSTASISP1493-P1493.

Miners AH, Sabin CA, Tolley K, Pasi KJ, Lee CA(1997). Assessing the change in bleeding patterns in patients with severe haemophilia and severe von Willebrand's disease (vWD) at a comprehensive care centre between 1980 and 1995. THROMBOSIS AND HAEMOSTASISPS978-PS978.

Perry DJ, Pasi KJ(1997). Resistance to activated protein C and factor V Leiden. QJM vol. 90, (6) 379-385.

Perry DJ, Riddell AF, Pasi KJ(1997). TL-MTHFR and venous thromboembolic disease. THROMBOSIS AND HAEMOSTASISP2323-P2323.

Fields P, Coghlan C, Sabin C, Riddell A, Jackson B, Lipkin D, Perry DJ, Hoffbrand AV et al.(1996). 677C->T mutation of the 5,10-methylene tetrahydrofolate reductase gene: A potential risk factor for coronary artery disease. BLOOD vol. 88, (10) 664-664.

Pasi KJ, Ononye C, Jenkins PV, Sabin CA, Lee CA(1996). Analysis of CKR5 mutants in HIV infected haemophilic patients and HIV exposed but uninfected haemophilic patients. BLOOD vol. 88, (10) 2604-2604.

Enayat MS, Theophilus BD, Pasi KJ, Hill FG(1996). De novo mutation causing sporadic type 2A von Willebrancd's disease: report of three cases. Haemophilia vol. 2, (4) 244-249.

Warrier I, Ewenstein BM, Koerper MA, Shapiro A, Key N, Dimichele D, Miller RT, Pasi J et al.(1996). Factor IX inhibitors and anaphylaxis in haemophilia B. Haemophilia vol. 2, (4) 259-260.

Jenkins PV, Ononye C, Collins PW, Pasi KJ(1996). Dominant type 1 vonWillebrand's disease as a result of a deletion of a single codon in exon 28 of the VWF gene. BRITISH JOURNAL OF HAEMATOLOGY vol. 93, 1176-1176.

Pasi KJ(1996). Gene therapy for haemophilia. Baillieres Clin Haematol vol. 9, (2) 305-317.

Jenkins PV, Ononye C, Murdock PJ, Pasi KJ(1996). Type 1 von Willebrand's disease is often associated with mutations in the factor VIII binding region of von Willebrand factor. BRITISH JOURNAL OF HAEMATOLOGY vol. 93, 76-76.

Yee TT, Cohen BJ, Pasi KJ, Lee CA(1996). Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate. Br J Haematol vol. 93, (2) 457-459.

Lee CA, Sabin C, Phillips AN, Bhagani S, Pasi J(1996). Progression of hepatitis C virus and HIV infection in a group of haemophilic men infected with HIV for up to 16 years. BRITISH JOURNAL OF HAEMATOLOGY vol. 93, 189-189.

Williams MD, Evans J, Pasi KJ, Hill FGH(1996). T lymphocyte subsets in haemophilic boys treated exclusively with intermediate purity factor VIII concentrate by (BPL 8Y): Results of a ten year study. BRITISH JOURNAL OF HAEMATOLOGY vol. 93, 227-227.

Sabin CA, Pasi J, Phillips AN, Lilley P, Elford J, Lee CA(1996). The use of intermediate-purity clotting factor concentrates and HIV disease progression in men with haemophilia. Haemophilia vol. 2, (2) 78-81.

Chan LC, Bourke C, Lam CK, Liu HW, Brookes S, Jenkins V, Pasi J(1996). Lack of activated protein C resistance in healthy Hong Kong Chinese blood donors--correlation with absence of Arg506-Gln mutation of factor V gene. Thromb Haemost vol. 75, (3) 522-523.

Miller G, Steinbrecher RA, Murdock PJ, Tuddenham EG, Lee CA, Pasi KJ, Goldspink G(1995). Expression of factor VII by muscle cells in vitro and in vivo following direct gene transfer: modelling gene therapy for haemophilia. Gene Ther vol. 2, (10) 736-742.

Collins PW, Noble KE, Reittie JR, Hoffbrand AV, Pasi KJ, Yong KL(1995). Induction of tissue factor expression in human monocyte/endothelium cocultures. Br J Haematol vol. 91, (4) 963-970.

Collins PW, Goldman E, Lilley P, Pasi KJ, Lee CA(1995). Clinical experience of factor XI deficiency: the role of fresh frozen plasma and factor XI concentrate. Haemophilia vol. 1, (4) 227-231.

Evans JA, Pasi KJ, Hill FG(1995). Evidence for the aetiological role of blood-borne virus infections in causing reduced lectin-induced T-cell proliferation in haemophilic boys. Br J Haematol vol. 91, (1) 197-202.

Ononye C, Jenkins PV, Goldman E, Pasi KJ(1995). Carrier detection and prenatal diagnosis by intron 22 inversion analysis of the factor VIII gene. Haemophilia vol. 1, (3) 204-206.

Pasi KJ, Evans JA, Forte M, Kumararatne DS, Hill FG(1995). Cytolytic activity against mycobacterial antigens: differences between haemophiliacs with and without HIV infection. Haemophilia vol. 1, (3) 178-183.

Pasi KJ, Perry DJ, Lee CA(1995). Thromboembolism and the combined oral contraceptive pill. Lancet vol. 345, (8962)

COLLINS PW, LILLEY P, GOLDMAN E, PASI KJ, LEE CA(1995). CLINICAL-EXPERIENCE OF FACTOR-XI DEFICIENCY - THE USE OF FRESH-FROZEN PLASMA AND FACTOR-XI CONCENTRATE. THROMBOSIS AND HAEMOSTASIS vol. 73, (6) 1442-1442.

LEE CA, SAHIN OA, PASI KJ, PHILLIPS AN, LILLEY P, BOFILL M(1995). IS HIV THE CAUSE OF AIDS - THE EFFECT OF INFECTION WITH HIV ON THE IMMUNE-SYSTEMS OF MEN WITH HEMOPHILIA-A AFTER CONTROLLING FOR CLOTTING FACTOR CONCENTRATE USAGE. THROMBOSIS AND HAEMOSTASIS vol. 73, (6) 1458-1458.

KOVACS IB, RIDLER CD, PASI JK(1995). MONITORING POTENCY OF FACTOR-VIII-REPLACEMENT IN RESTORING HEMOSTATIC COMPETENCE IN-VITRO AND IN-VIVO. THROMBOSIS AND HAEMOSTASIS vol. 73, (6) 1172-1172.

COLLINS PW, FIELDS P, GOLDMAN E, LEE CA, PASI KJ(1995). THE USE OF RFVIIA TO TREAT A FACTOR-IX INHIBITOR FOLLOWING ANAPHYLAXIS WITH FACTOR-IX CONCENTRATE. THROMBOSIS AND HAEMOSTASIS vol. 73, (6) 1029-1029.

Lee CA, Sabin CA, Phillips AN, Elford J, Pasi J(1995). Morbidity and mortality from transfusion-transmitted disease in haemophilia. Lancet vol. 345, (8960)

Alusi GH, Grant WE, Lee CA, Pasi KJ, Stearns MP(1995). Bleeding after tonsillectomy in severe von Willebrand's disease. J Laryngol Otol vol. 109, (5) 437-439.

Pasi KJ (1995). Future perspectives in paediatric haemophilia. Haemophilia. vol. 1 Suppl 2, 12-13.

Yee TT, Lee CA, Pasi KJ(1995). Life-threatening human parvovirus B19 infection in immunocompetent haemophilia. Lancet vol. 345, (8952) 794-795.

MILLER G, STEINBRECHER RA, MURDOCK PJ, PASI KJ, TUDDENHAM EGD, LEE CA, GOLDSPINK G, DORMANDY K(1995). EXPRESSION OF FACTOR-VII IN-VITRO AND IN-VIVO FOLLOWING DIRECT GENE-TRANSFER INTO MUSCLE - A MODEL FOR HEMOPHILIA. JOURNAL OF CELLULAR BIOCHEMISTRY381-381.

GUTSMANN V, PASI J, RIDDEL A, AGNEW A(1994). A NOVEL ANTICOAGULANT FROM THE BLOOD FLUKE SCHISTOSOMA. BLOOD vol. 84, (10) A193-A193.

Sabin C, Pasi J, Phillips A, Elford J, Janossy G, Lee C(1994). CD4+ counts before and after switching to monoclonal high-purity factor VIII concentrate in HIV-infected haemophilic patients. Thromb Haemost vol. 72, (2) 214-217.

PASI KJ, SABIN C, LEE CA, HILL FGH(1993). EFFECT OF INTERMEDIATE PURITY FACTOR-VIII CONCENTRATE TREATMENT 1980-90 IN A COHORT OF HIV-INFECTED HEMOPHILIC PATIENTS. THROMBOSIS AND HAEMOSTASIS vol. 69, (6) 856-856.

PASI KJ, ENAYAT MS, JENKINS PV, LEE CA, HILL FGH(1993). FAMILY STUDIES IN VON-WILLEBRANDS DISEASE USING VARIABLE NUMBER TANDEM REPEATS AND RESTRICTION POLYMORPHISM ANALYSIS OF THE VON-WILLEBRAND-FACTOR GENE. THROMBOSIS AND HAEMOSTASIS vol. 69, (6) 1179-1179.

PASI KJ, EVANS JA, WADHWA M, THORPE R, HILL FGH(1993). HEMOPHILIA-A - IMMUNE ABNORMALITIES WITH AND WITHOUT HIV AND HCV INFECTION. THROMBOSIS AND HAEMOSTASIS vol. 69, (6) 854-854.

ENAYAT SM, PASI JK, HILL FGH(1993). PHENOTYPIC AND MOLECULAR HETEROGENEITY IN TYPE-IIA VON-WILLEBRANDS DISEASE. THROMBOSIS AND HAEMOSTASIS vol. 69, (6) 1179-1179.

Evans JA, Pasi KJ, Williams MD, Hill FG(1991). Consistently normal CD4+, CD8+ levels in haemophilic boys only treated with a virally safe factor VIII concentrate (BPL 8Y). Br J Haematol vol. 79, (3) 457-461.

EVANS JA, PASI KJ, HILL FGH(1991). CAN FACTOR-VIII CONCENTRATES CAUSE IMMUNE MODULATION IN THE ABSENCE OF BLOOD BORNE VIRUS-INFECTION. THROMBOSIS AND HAEMOSTASIS vol. 65, (6) 823-823.

EVANS JA, PASI KJ, HILL FGH(1991). CAN T-LYMPHOCYTE PROLIFERATION AID THE PROGNOSTIC VALUE OF CD4 LEVELS IN TREATMENT DECISIONS IN HIV INFECTED HEMOPHILIACS. THROMBOSIS AND HAEMOSTASIS vol. 65, (6) 1163-1163.

PASI KJ, EVANS JA, FORTE M, HILL FGH(1991). CHANGES IN T-CELL CYTOTOXICITY AND PROLIFERATION TO PPD IN HIV SEROPOSITIVE BOYS WHO HAD PREVIOUSLY HAD PULMONARY TUBERCULOSIS. THROMBOSIS AND HAEMOSTASIS vol. 65, (6) 997-997.

PASI KJ, ENAYAT MS, HILL FGH(1991). INHERITANCE PATTERNS IN SPORADIC TYPE-IIA VONWILLEBRAND-DISEASE. THROMBOSIS AND HAEMOSTASIS vol. 65, (6) 1126-1126.

PASI KJ, EVANS JA, HILL FGH(1991). SELECTIVE LOSS OF SPECIFIC ANTIBODY TO THYMUS DEPENDENT ANTIGENS AND POLYCLONAL-B CELL STIMULATION IN HIV INFECTED HEMOPHILIC BOYS. THROMBOSIS AND HAEMOSTASIS vol. 65, (6) 997-997.

Pasi KJ, Hill FG(1990). In vitro and in vivo inhibition of monocyte phagocytic function by factor VIII concentrates: correlation with concentrate purity. Br J Haematol vol. 76, (1) 88-93.

Pasi KJ, Enayat MS, Horrocks PM, Wright AD, Hill FG(1990). Qualitative and quantitative abnormalities of von Willebrand antigen in patients with diabetes mellitus. Thromb Res vol. 59, (3) 581-591.

PASI KJ, EVANS JA, SKIDMORE SJ, HILL FGH(1990). PREVENTION OF HEPATITIS-C VIRUS-INFECTION IN HEMOPHILIACS. LANCET vol. 335, (8703) 1473-1474.

Pasi KJ, Williams MD, Enayat MS, Hill FG(1990). Clinical and laboratory evaluation of the treatment of von Willebrand's disease patients with heat-treated factor VIII concentrate (BPL 8Y). Br J Haematol vol. 75, (2) 228-233.

Pasi KJ, Collins MA, Ewer AK, Hill FG(1990). Growth in haemophilic boys after HIV infection. Arch Dis Child vol. 65, (1) 115-118.

Skidmore SJ, Pasi KJ, Mawson SJ, Williams MD, Hill FG(1990). Serological evidence that dry heating of clotting factor concentrates prevents transmission of non-A, non-B hepatitis. J Med Virol vol. 30, (1) 50-52.

Williams MD, Cohen BJ, Beddall AC, Pasi KJ, Mortimer PP, Hill FG(1990). Transmission of human parvovirus B19 by coagulation factor concentrates. Vox Sang vol. 58, (3) 177-181.

Pasi KJ, Enayat MS(1989). Factor VIII-von Willebrand factor in haemolytic uraemic syndrome. BMJ vol. 298, (6673)

Pasi KJ, Hamon MD, Perry DJ, Hill FG(1987). Factor VIII and IX inhibitors after exposure to heat-treated concentrates. Lancet vol. 1, (8534)